Section 1: Identification

Material: Abacavir Sulfate, Lamivudine and Zidovudine Tablets
300 mg, 150 mg and 300 mg

Manufacturer: Lupin Limited
Pithampur (M.P) – 454 775
INDIA.

Distributor: Lupin Pharmaceuticals, Inc.
111 South Calvert Street,
Harborplace Tower, 21st Floor,
Baltimore, Maryland 21202
United States
Tel. 001-410-576-2000
Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Fire and Explosion: Expected to be non-combustible.

Health:
Abacavir, lamivudine and zidovudine tablets are contraindicated in patients:
- who have the HLA-B*5701 allele
- with prior hypersensitivity reaction to abacavir, lamivudine, or zidovudine.
- with moderate or severe hepatic impairment.

Environment: No information is available about the potential of this product to produce adverse environmental effects.

Section 3: Composition/Information on Ingredients

Ingredients:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>CAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abacavir Sulfate USP</td>
<td>188062-50-2</td>
</tr>
<tr>
<td>Lamivudine USP</td>
<td>134678-17-4</td>
</tr>
<tr>
<td>Zidovudine USP</td>
<td>30516-87-1</td>
</tr>
</tbody>
</table>
# Section 4: First-Aid Measures

## Section 4, First-aid measures

### Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

### Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

### Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

### Eye Contact
Flush eyes with plenty of water. Get medical attention.

## NOTES TO HEALTH PROFESSIONALS

### Medical Treatment
Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

### OVERDOSAGE
There is no known specific treatment for overdose with abacavir, lamivudine and zidovudine tablets. If overdose occurs, the patient should be monitored and standard supportive treatment applied as required.

#### Abacavir
It is not known whether abacavir can be removed by peritoneal dialysis or hemodialysis.

#### Lamivudine
Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event.

#### Zidovudine
Acute overdoses of zidovudine have been reported in pediatric patients and adults. These involved exposures up to 50 grams. No specific symptoms or signs have been identified following acute overdosage with zidovudine apart from those listed as adverse events such as fatigue, headache, vomiting, and occasional reports of hematological disturbances. Patients recovered without permanent sequelae. Hemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine, while elimination of its primary metabolite, 3′-azido-3′-deoxy-5′-O-β-D-glucopyranuronosylthymidine (GZDV), is enhanced.
### Section 5: Fire-Fighting Measures

**Section 5, Fire-fighting measures**

<table>
<thead>
<tr>
<th>Fire and Explosion Hazards</th>
<th>Assume that this product is capable of sustaining combustion.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extinguishing Media</td>
<td>Water spray, carbon dioxide, dry chemical powder or appropriate foam.</td>
</tr>
<tr>
<td>Special Firefighting Procedures</td>
<td>For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.</td>
</tr>
<tr>
<td>Hazardous Combustion Products</td>
<td>Hazardous combustion or decomposition products are expected when the product is exposed to fire.</td>
</tr>
</tbody>
</table>

### Section 6: Accidental Release Measures

**Section 6, Accidental release measures**

<table>
<thead>
<tr>
<th>Personal Precautions</th>
<th>Wear protective clothing and equipment consistent with the degree of hazard.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental Precautions</td>
<td>For large spills, take precautions to prevent entry into waterways sewers, or surface drainage systems.</td>
</tr>
<tr>
<td>Clean-up Methods</td>
<td>Collect and place it in a suitable, properly labeled container for recovery or disposal.</td>
</tr>
</tbody>
</table>

### Section 7: Handling and Storage

**Section 7, Handling and storage**

<table>
<thead>
<tr>
<th>Handling</th>
<th>No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Storage</td>
<td>Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].</td>
</tr>
</tbody>
</table>

### Section 8: Exposure Controls/ Personal Protection

**Section 8, Exposure controls/personal protection**

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.
Section 9: Physical and Chemical Properties

Physical Form
Abacavir, lamivudine and zidovudine is available as tablets. Each tablet contains 300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine. The tablets are blue-green colored, oval shaped, biconvex, film-coated, debossed with “LU” on one side and “N51” on the other side. They are packaged as follows:

- Bottles of 60 Tablets NDC 68180-286-07
- Bottles of 100 Tablets NDC 68180-286-01
- Bottles of 500 Tablets NDC 68180-286-02

Section 10: Stability and Reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity
Abacavir:
Abacavir was administered orally at 3 dosage levels to separate groups of mice and rats in 2-year carcinogenicity studies. Results showed an increase in the incidence of malignant and non-malignant tumors. Malignant tumors occurred in the preputial gland of males and the clitoral gland of females of both species, and in the liver of female rats. In addition, non-malignant tumors also occurred in the liver and thyroid gland of female rats. These observations were made at systemic exposures in the range of 6 to 32 times the human exposure at the recommended dose of 600 mg.

Lamivudine:
Long-term carcinogenicity studies with lamivudine in mice and rats showed no evidence of carcinogenic potential at exposures up to 10 times (mice) and 58 times (rats) the human exposures at the recommended dose of 300 mg.

Zidovudine:
Zidovudine was administered orally at 3 dosage levels to separate groups of mice and rats (60 females and 60 males in each group). Initial single daily doses were 30, 60, and 120 mg per kg per day in mice and 80, 220, and 600 mg per kg per day in rats. The doses in mice were reduced to 20, 30, and 40 mg per kg per day after day 90 because of treatment-related anemia, whereas in rats only the high dose was reduced to 450 mg per kg per day on day 91 and then to 300 mg per kg per day on day 279.
In mice, 7 late-appearing (after 19 months) vaginal neoplasms (5 nonmetastasizing squamous cell carcinomas, 1 squamous cell papilloma, and 1 squamous polyp) occurred in animals given the highest dose. One late-appearing squamous cell papilloma occurred in the vagina of a middle-dose animal. No vaginal tumors were found at the lowest dose.

In rats, 2 late-appearing (after 20 months), nonmetastasizing vaginal squamous cell carcinomas occurred in animals given the highest dose. No vaginal tumors occurred at the low or middle dose in rats. No other drug-related tumors were observed in either sex of either species.

At doses that produced tumors in mice and rats, the estimated drug exposure (as measured by AUC) was approximately 3 times (mouse) and 24 times (rat) the estimated human exposure at the recommended therapeutic dose of 100 mg every 4 hours.

It is not known how predictive the results of rodent carcinogenicity studies may be for humans.

Two transplacental carcinogenicity studies were conducted in mice. One study administered zidovudine at doses of 20 mg per kg per day or 40 mg per kg per day from gestation day 10 through parturition and lactation with dosing continuing in offspring for 24 months postnatally. At these doses, exposures were approximately 3 times the estimated human exposure at the recommended doses. After 24 months at the 40-mg per kg per day dose, an increase in incidence of vaginal tumors was noted with no increase in tumors in the liver or lung or any other organ in either gender. These findings are consistent with results of the standard oral carcinogenicity study in mice, as described earlier. A second study administered zidovudine at maximum tolerated doses of 12.5 mg per day or 25 mg per day (approximately 1,000 mg per kg nonpregnant body weight or approximately 450 mg per kg of term body weight) to pregnant mice from days 12 through 18 of gestation. There was an increase in the number of tumors in the lung, liver, and female reproductive tracts in the offspring of mice receiving the higher dose level of zidovudine.

**Mutagenicity**

### Abacavir:
Abacavir induced chromosomal aberrations both in the presence and absence of metabolic activation in an in vitro cytogenetic study in human lymphocytes. Abacavir was mutagenic in the absence of metabolic activation, although it was not mutagenic in the presence of metabolic activation in an L5178Y mouse lymphoma assay. Abacavir was clastogenic in males and not clastogenic in females in an in vivo mouse bone marrow micronucleus assay. Abacavir was not mutagenic in bacterial mutagenicity assays in the presence and absence of metabolic activation.

### Lamivudine:
Lamivudine was mutagenic in an L5178Y mouse lymphoma assay and clastogenic in a cytogenetic assay using cultured human lymphocytes. Lamivudine was not mutagenic in a microbial mutagenicity assay, in an in vitro cell transformation assay, in a rat micronucleus test, in a rat bone marrow cytogenetic assay, and in an assay for unscheduled DNA synthesis in rat liver.
Zidovudine:
Zidovudine was mutagenic in an L5178Y mouse lymphoma assay, positive in an in vitro cell transformation assay, clastogenic in a cytogenetic assay using cultured human lymphocytes, and positive in mouse and rat micronucleus tests after repeated doses. It was negative in a cytogenetic study in rats given a single dose.

Impairment of Fertility 
Abacavir or Lamivudine:
Abacavir or lamivudine did not affect male or female fertility in rats at a dose associated with exposures approximately 8 or 130 times, respectively, higher than the exposures in humans at the doses of 600 mg and 300 mg (respectively).

Zidovudine:
Zidovudine, administered to male and female rats at doses up to 7 times the usual adult dose based on body surface area considerations, had no effect on fertility judged by conception rates.

Section 12: Ecological Information
No relevant studies identified.

Section 13: Disposal Considerations
Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

IATA/ICAO - Not Regulated
IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated
IMDG Proper shipping Name : N/A
IMDG UN/ID No : N/A
IMDG Hazard Class : N/A
IMDG Flash Point : N/A
IMDG Label : N/A

DOT - Not Regulated
DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A
### Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

### Section 16: Other Information

**Section 16, Other information**

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.